Richard M. Pazdur
United States Food and Drug Administration
Affiliation United States Food and Drug Administration Top Publications Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) – 4,886 citations FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma (2007) – 1,378 citations FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors ... <a title="Richard M. Pazdur" class="read-more" href="https://journalsworld.com/researchers/richard-m-pazdur/" aria-label="Read more about Richard M. Pazdur">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
United States Food and Drug Administration
Top Publications
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) - 4,886 citations
- FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma (2007) - 1,378 citations
- FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors (2019) - 1,188 citations
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome (2018) - 906 citations
- Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. (2001) - 861 citations
At a glance
- Full name
- Richard M. Pazdur
- ORCID
- 0000-0002-4771-9923
- OpenAlex ID
- https://openalex.org/A5051520990
Research interests
- Cancer Immunotherapy and Biomarkers, Statistical Methods in Clinical Trials, Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Acute Myeloid Leukemia Research
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-07. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- 4,886OpenAlex citations
- 1,378OpenAlex citations
- FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors ↗2019 · Clinical Cancer Research1,188OpenAlex citations
- 906OpenAlex citations
- 861OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors ↗2019 · Clinical Cancer Research
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-07 · Last data update: 2026-10-07 23:05:52
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.